Shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT - Get Free Report) gapped up prior to trading on Wednesday . The stock had previously closed at $12.16, but opened at $16.28. ClearPoint Neuro shares last traded at $17.99, with a volume of 4,452,197 shares changing hands.
Analyst Ratings Changes
CLPT has been the subject of several recent analyst reports. Wall Street Zen raised shares of ClearPoint Neuro from a "sell" rating to a "hold" rating in a research note on Saturday, September 13th. Stifel Nicolaus lifted their price objective on ClearPoint Neuro from $8.00 to $9.00 and gave the company a "buy" rating in a report on Friday, August 1st. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, ClearPoint Neuro presently has an average rating of "Buy" and an average target price of $19.67.
Read Our Latest Stock Report on CLPT
ClearPoint Neuro Stock Performance
The company has a debt-to-equity ratio of 1.46, a current ratio of 7.30 and a quick ratio of 6.45. The stock has a market capitalization of $527.38 million, a PE ratio of -23.01 and a beta of 0.89. The stock has a 50 day moving average of $10.88 and a two-hundred day moving average of $11.93.
ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.01). The business had revenue of $9.22 million during the quarter, compared to analysts' expectations of $9.20 million. ClearPoint Neuro had a negative net margin of 66.15% and a negative return on equity of 94.44%. ClearPoint Neuro has set its FY 2025 guidance at EPS. Research analysts expect that ClearPoint Neuro, Inc. will post -0.66 EPS for the current fiscal year.
Institutional Investors Weigh In On ClearPoint Neuro
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Parsons Capital Management Inc. RI increased its stake in ClearPoint Neuro by 0.7% during the second quarter. Parsons Capital Management Inc. RI now owns 143,486 shares of the company's stock worth $1,713,000 after acquiring an additional 950 shares during the last quarter. Informed Momentum Co LLC increased its stake in ClearPoint Neuro by 2.4% during the first quarter. Informed Momentum Co LLC now owns 49,177 shares of the company's stock worth $585,000 after acquiring an additional 1,143 shares during the last quarter. MGO One Seven LLC increased its stake in ClearPoint Neuro by 9.6% during the second quarter. MGO One Seven LLC now owns 17,949 shares of the company's stock worth $214,000 after acquiring an additional 1,569 shares during the last quarter. Pekin Hardy Strauss Inc. boosted its position in shares of ClearPoint Neuro by 3.6% in the second quarter. Pekin Hardy Strauss Inc. now owns 50,575 shares of the company's stock worth $604,000 after buying an additional 1,750 shares during the period. Finally, Allworth Financial LP boosted its position in shares of ClearPoint Neuro by 3,076.9% in the second quarter. Allworth Financial LP now owns 2,065 shares of the company's stock worth $25,000 after buying an additional 2,000 shares during the period. 30.08% of the stock is currently owned by institutional investors and hedge funds.
About ClearPoint Neuro
(
Get Free Report)
ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ClearPoint Neuro, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ClearPoint Neuro wasn't on the list.
While ClearPoint Neuro currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
